COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Article Mental and Behavioral Health Exploring the Psychedelics Landscape: Looking Ahead to Funding in 2024 February 20, 2024
Executive Insights Biotech and Pharmaceuticals Variability in Large Pharma Launch Performance January 16, 2024
Published Articles Biotech and Pharmaceuticals EU Pharmaceutical Legislation Revisions: What Are the Implications for Biopharma? December 20, 2023